Facts and figures

in page functions

The evidence is clear: vaccines are one of the most cost-effective investments in health and development in history. Gavi helps save children’s lives and protect people’s health by increasing equitable use of vaccines in lower-income countries.

Over 7 million deaths averted

Since its launch in 2000, Gavi has helped developing countries to prevent more than 7 million future deaths from hepatitis B, Haemophilus influenzae type b, human papillomavirus, Japanese encephalitis, measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever.

Source: Gavi, the Vaccine Alliance / Bill & Melinda Gates Foundation 2015

More than 500 million children immunised

Since 2000, Gavi support has contributed to the immunisation of an additional 500 million children.

Source: WHO/UNICEF 2015

Reaching 81% coverage with DTP3

In 2014, DTP3 coverage in Gavi-supported countries reached its highest-ever level, 81% – just 5 percentage points below the global average. This represents an increase of 21 percentage points since our foundation in 2000.

Source: WHO/UNICEF 2015

65 million children immunised every year

Nearly 65 million children in Gavi-supported countries received three doses of a DTP-containing vaccine (including pentavalent vaccine) in 2014. This equals almost 200 million contacts with the primary health system every year and can provide a robust platform for other health interventions.

Source: WHO/UNICEF 2015

Health systems and immunisation services strengthened in more than 60 countries

The Vaccine Alliance has helped strengthen health systems and immunisation services in more than 60 countries and increased injection safety.

Source: Gavi

Almost 4 million deaths averted between 2011 and 2015

The Vaccine Alliance’s support for vaccines contributed to averting nearly 4 million future deaths between 2011 and 2015.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2015

Nearly a quarter of a billion immunised 2011-2015

Gavi support helped countries to immunise close to 250 million children between 2011 and 2015.

Source: WHO/UNICEF 2015

More than 200 vaccine introductions between 2011 and 2015

Gavi supported more than 200 vaccine introductions and campaigns in the 2011–2015 period – four times as many as in the previous five years.

Source: Gavi

Pentavalent vaccine: 73 countries, 230 million people, 5 antigens

In July 2014, South Sudan became the 73rd and final Gavi-supported country to introduce the five-in-one pentavalent vaccine. By the end of 2014, more than 230 million children had been immunised with pentavalent vaccine with Gavi support.

Source: WHO/UNICEF 2015

47 million children vaccinated against pneumococcal disease

By the end of 2014, Vaccine Alliance support had contributed to immunising 47 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions more than 1 year ahead of schedule. By the end of 2015, three-quarters of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2015

20 million children vaccinated against rotavirus

Vaccine Alliance support has contributed to immunising over 20 million children against rotavirus diarrhoea. By the end of 2015, more than half of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2015

More than 220 million people immunised against meningitis A

By the end of 2014, 15 countries in the African meningitis belt had collectively immunised more than 220 million people against meningitis A with support from Gavi.

Source: WHO/UNICEF 2015

Meningitis A, C, Y, W combination vaccine stockpile prevents outbreaks

Gavi funds a stockpile of multivalent vaccine to prevent outbreaks of meningitis A, C, W and Y. Doses from the stockpile played a critical role in controlling the 2015 meningitis C outbreak in Niger.

Source: Gavi

Human papillomavirus vaccine demonstration programmes: 1 million girls reached

Since the first human papillomavirus (HPV) vaccine demonstration project in Kenya in 2013, an estimated 1 million girls have been vaccinated with Gavi support – a figure expected to rise to 30 million by the end of 2020. Gavi has already started to fund national HPV programmes in Rwanda and Uganda.

Source: Gavi

Inactivated polio vaccine programme progressing at record speed

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2015, 39 countries had introduced the vaccine with support from the Vaccine Alliance.

Source: Gavi

22 million reached with measles 2nd dose vaccine

Since 2007, countries have immunised 22 million children with a 2nd dose of measles vaccine with Gavi support. Gavi-funded measles campaigns have helped vaccinate another 67 million children in countries considered at high risk of measles outbreaks.

Source: WHO/UNICEF 2015

Measles-rubella vaccine reaches 140 million people

By the end of 2014, Gavi-funded measles-rubella catch-up campaigns, targeting the next generation of mothers and children aged 9 months to 14 years, had reached 140 million people.

Source: WHO/UNICEF 2015

Yellow fever vaccine: mass prevention campaigns

Starting in 2011, Gavi-supported mass prevention campaigns have protected 88 million people in 14 “high-risk” countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation since 2000.

Source: Gavi

Oral cholera vaccine stockpile helps vaccinate 600,000 people

Since its creation in 2013, the global oral cholera vaccine has been used to vaccinate more than 600,000 people; in 2014, doses were allocated to Ethiopia, Guinea, Haiti, Nepal and South Sudan.

Source: Gavi

Japanese encephalitis: Lao first to introduce vaccine with Gavi support

In April 2015, the Lao People’s Democratic Republic became the first country to introduce Japanese encephalitis vaccine with Gavi support.

Source: Gavi

Investing in immunisation is one of the most cost-effective ways of improving living standards, health and the global economy.

100 million illness cases averted

Vaccines have a long-term positive impact beyond health outcomes. Expanded immunisation in Gavi-supported countries from 2016 to 2020 could deliver more than 100 million illness cases averted. This will reduce the burden of care on parents, improving their productivity and freeing them from crippling medical costs. And by protecting children from infectious diseases, vaccines will also help raise IQ levels.

Source: Lee LA et al. The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the Gavi, the Vaccine Alliance. Vaccine 2013

US$ 80-100 billion in economic benefits

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

Return on investment of immunisation: US$ 16 for every US$ 1 spent

A study in Health Affairs covering 94 low- and middle-income countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 16 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 44 per US$ 1 spent.

Source: Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

In January 2015, donors, implementing countries and industry responded to our call to save more lives by pledging over US$ 7.5 billion for the 2016–2020 period.

US$ 7.5 billion in donor support 2011-2015

Top 10 donors: United Kingdom: 2.32b; Bill & Melinda Gates Foundation: 1.32b; Norway: 757m; United States of America: 733m; France: 450m; Italy: 423m; Australia: 274m; Sweden: 266m; Netherlands: 222m; Canada: 195m (contributions in US$ as of 30 Sept 2015)

US$ 2.5 billion from IFFIm

As of 31 December 2015, IFFIm has contributed US$ 2.5 billion to Gavi to fund vaccines and other programmes, and IFFIm’s “vaccine bonds” have raised US$ 5.2 billion on the capital markets since 2006.

Over US$ 10 billion committed to countries

As of the end of November 2015, Gavi’s total commitments amount to over US$ 10 billion. This includes current commitments from year 2000 up to 2020 for both country programmes and investment cases.

More than 70 countries co-financing

In 2014, more than 70 countries were co-financing new and underused vaccines supplied by Gavi. Their contributions totalled over US$ 80 million.

Over 20 countries to self-finance by 2020

More than 20 countries are projected to be fully self-financing their vaccines by 2020.

Coverage and equity are at the core of our 2016–2020 strategy. While we continue to help countries introduce new vaccines, our focus is expanding to reach every child with these vaccines.

1.5 million children under five lose their lives to vaccine preventable diseases every year.

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

Almost 19 million under-immunised

Nearly 19 million infants remain under-immunised with three doses of diphtheria-tetanus-pertussis vaccine in the world each year. One in five of all children in Gavi-supported countries miss out on this basic package of vaccines.

Source: WHO/UNICEF 2015

95% of children miss out on recommended vaccines

Over 95% of children in Gavi-supported countries do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015

90% of under-immunised children are in 20 countries

Approximately 90% of the under-immunised children in Gavi-supported countries live in just 20 countries, many of which are also fragile or conflict-afflicted. We are intensifying our efforts to improve coverage and equity in these priority countries.  

Source: WHO/UNICEF 2015

Over a quarter of child deaths are due to pneumonia and diarrhoea

Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

One woman dies every 2 minutes from cervical cancer

One woman dies from cervical cancer every two minutes - or 266,000 a year- over 85% in the developing world. Two-thirds of all cervical cancer deaths can be prevented with HPV vaccine.

Source: WHO

90 thousand born with birth defects due to rubella

Every year, 90,000 babies in Gavi countries are born with severe birth defects known as congenital rubella syndrome because their mothers were infected with rubella during pregnancy. The combined measles-rubella vaccine, which Gavi supports, can help prevent this devastating disease.

Source: WHO

COST OF IMMUNISING A CHILD WITH THREE KEY VACCINES DOWN BY 39%

Since 2010, the total cost of immunising a child living in a Gavi-supported country with pentavalent, pneumococcal, and rotavirus vaccines has dropped by 39%.

Pneumococcal vaccine: more than 90% reduction to US$ 3.50 per dose

Through the Advance Market Commitment, pneumococcal vaccines are available to Gavi-eligible countries at no more than US$ 3.50 per dose, a more than 90% reduction compared with the public price in the United States. In 2013, Gavi secured a lowest price offer for one type of pneumococcal vaccine of US$ 3.30 per dose from 2014 onwards.

Inactivated polio vaccine: available to Gavi countries from €0.75

Following a tender for IPV, the inactivated polio vaccine will be available to Gavi-supported countries from as little as €0.75 (approximately US$ 1) per dose. Middle-income countries will be able to buy the vaccine through UNICEF for between €1.49 and €2.40 (approximately US$ 2.04-3.28) per dose.

Pentavalent (DTP-hep B-Hib) vaccine: a reduction of more than 40% to US$ 1.90 per dose

The weighted average price of pentavalent vaccine per dose has dropped from US$ 3.56 in 2003 to US $ 1.90 in 2014.

Rotavirus vaccine: 67% reduction to US$ 2.50

As a result of long-term supply agreements with manufacturers signed in 2012, Gavi buys the bulk of its rotavirus vaccine doses at US$ 2.50 (US$ 5.0 per course), a two-thirds reduction compared to the previous lowest price offered to Gavi of US$ 7.50 a dose (US$15 a course), and will have an expected market impact valued at US$ 650 million.

Human papillomavirus (HPV) vaccine: two-thirds reduction to US$ 4.50

Gavi, the Vaccine Alliance works with manufacturers to bring down HPV prices. In 2013, a price of US$ 4.50 per dose for one of the vaccines was agreed, a two-thirds reduction on the current lowest public price.

From 5 to 15 vaccine manufacturers supplying Gavi – from 1 to 8 based in emerging markets

2001: 5 vaccine manufacturers - 1 based in an emerging market.

Mid-2015: 15 vaccine manufacturers – 8 based in emerging markets.

MENINGITIS A VACCINE APPROVED FOR USE IN INNOVATIVE CONTROLLED TEMPERATURE CHAIN

In 2012 MenAfriVac, a meningitis A vaccine, was approved for use by WHO in a controlled temperature chain. This innovative approach permits the use of the vaccine outside the traditional 2°C to 8°C cold chain for limited periods of time.

close icon

modal window here